Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
doi: https://doi.org/10.1101/2021.04.24.21256047
Ammar Ali Almarzooq
1Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain
Posted April 27, 2021.
Interleukin-6 receptor genetic variation and tocilizumab treatment response to COVID-19
Ammar Ali Almarzooq
medRxiv 2021.04.24.21256047; doi: https://doi.org/10.1101/2021.04.24.21256047
Subject Area
Subject Areas
- Addiction Medicine (324)
- Allergy and Immunology (632)
- Anesthesia (168)
- Cardiovascular Medicine (2397)
- Dermatology (207)
- Emergency Medicine (381)
- Epidemiology (11789)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3763)
- Geriatric Medicine (350)
- Health Economics (637)
- Health Informatics (2406)
- Health Policy (937)
- Hematology (342)
- HIV/AIDS (785)
- Medical Education (367)
- Medical Ethics (105)
- Nephrology (401)
- Neurology (3521)
- Nursing (199)
- Nutrition (528)
- Oncology (1830)
- Ophthalmology (538)
- Orthopedics (220)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (66)
- Pathology (447)
- Pediatrics (1036)
- Primary Care Research (424)
- Public and Global Health (6175)
- Radiology and Imaging (1288)
- Respiratory Medicine (831)
- Rheumatology (380)
- Sports Medicine (324)
- Surgery (403)
- Toxicology (50)
- Transplantation (172)
- Urology (147)